Evolution of hormonal therapy for prostate cancer.

IF 1.6 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Australian Journal of General Practice Pub Date : 2024-05-01 DOI:10.31128/AJGP-11-23-7028

David Homewood, Ming Hei Fu, Niranjan Sathianathen, Shane La Bianca, Benjamin Tran, Niall M Corcoran

{"title":"Evolution of hormonal therapy for prostate cancer.","authors":"David Homewood, Ming Hei Fu, Niranjan Sathianathen, Shane La Bianca, Benjamin Tran, Niall M Corcoran","doi":"10.31128/AJGP-11-23-7028","DOIUrl":null,"url":null,"abstract":"Background: Prostate cancer (PCa) is the most common malignancy after skin cancer in men in Australia. Its management varies according to tumour stage. Due to the significant dependence on androgen receptor signalling, agents that interfere with this pathway (most commonly medical castration in the form of androgen deprivation therapy [ADT]) are the mainstay treatment of advanced disease.Objective: This review provides a contemporary update on ADT, with further discussion of emerging novel therapies for primary care.Discussion: ADT is currently indicated for the treatment of metastatic prostate cancer, disease recurrence following attempted local curative therapy, as well as combined use with radiotherapy for intermediate/high-risk disease. There has been rapid development of new pharmaceuticals targeting the androgen receptor. These are reviewed historically with an emphasis placed on emerging therapies, their common side effects, and how to manage them in the general practice setting.","PeriodicalId":54241,"journal":{"name":"Australian Journal of General Practice","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australian Journal of General Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.31128/AJGP-11-23-7028","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Prostate cancer (PCa) is the most common malignancy after skin cancer in men in Australia. Its management varies according to tumour stage. Due to the significant dependence on androgen receptor signalling, agents that interfere with this pathway (most commonly medical castration in the form of androgen deprivation therapy [ADT]) are the mainstay treatment of advanced disease.

Objective: This review provides a contemporary update on ADT, with further discussion of emerging novel therapies for primary care.

Discussion: ADT is currently indicated for the treatment of metastatic prostate cancer, disease recurrence following attempted local curative therapy, as well as combined use with radiotherapy for intermediate/high-risk disease. There has been rapid development of new pharmaceuticals targeting the androgen receptor. These are reviewed historically with an emphasis placed on emerging therapies, their common side effects, and how to manage them in the general practice setting.

查看原文本刊更多论文

前列腺癌激素疗法的演变。

背景：前列腺癌（PCa）是澳大利亚男性继皮肤癌之后最常见的恶性肿瘤。其治疗方法因肿瘤分期而异。由于前列腺癌严重依赖雄激素受体信号，干扰这一途径的药物（最常见的是以雄激素剥夺疗法 [ADT] 为形式的药物阉割）是晚期疾病的主要治疗方法：本综述介绍了 ADT 的最新进展，并进一步讨论了用于初级保健的新兴新型疗法：ADT 目前适用于治疗转移性前列腺癌、尝试局部根治性治疗后的疾病复发，以及与放疗联合用于治疗中/高风险疾病。针对雄激素受体的新药开发迅速。本文对这些药物进行了历史回顾，重点介绍了新出现的疗法、其常见副作用以及如何在全科医疗环境中进行管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Australian Journal of General Practice Medicine-Family Practice

CiteScore

2.80

自引率

4.50%

发文量

284

期刊介绍： The Australian Journal of General Practice (AJGP) aims to provide relevant, evidence-based, clearly articulated information to Australian general practitioners (GPs) to assist them in providing the highest quality patient care, applicable to the varied geographic and social contexts in which GPs work and to all GP roles as clinician, researcher, educator, practice team member and opinion leader. All articles are subject to peer review before they are accepted for publication.